Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Oral AQX-1125 and Combination Oral Contraceptive Drug-Drug Interaction Study (DDI-COC)

12. juni 2018 oppdatert av: Aquinox Pharmaceuticals (Canada) Inc.

Open-Label, Fixed-Sequence 3-Period Study to Determine the Effects of Repeated Oral Dosing of AQX-1125 on the Pharamacokinetics, Safety and Tolerability of a Combination Oral Contraceptive in Healthy Female Subjects

This is an open-label, fixed sequence, 4 cycle, drug-drug interaction (DDI) study of AQX-1125 in healthy female subjects on combination oral contraceptives (COC).

Studieoversikt

Studietype

Intervensjonell

Registrering (Faktiske)

32

Fase

  • Fase 1

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

      • Groningen, Nederland
        • PRA Health Sciences - Early Development Serices

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 45 år (Voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Hunn

Beskrivelse

Inclusion Criteria:

  • Aged 18-45 years, inclusive, at time of signing Informed Consent
  • Adult females of child bearing potential, who are non-pregnant and non-lactating, and must agree to use adequate additional contraception from the start of Treatment Period A until 90 days after the last dose of AQX-1125
  • BMI 18.0 - 35.0 kg/m2
  • Good physical and mental health based on medical history, physical examination, clinical laboratory, ECG and vital signs, as judged by the investigator

Exclusion Criteria:

  • Previous participation in the current study
  • Any clinically significant history of breakthrough bleeding
  • Using tobacco or other nicotine containing products within 12 months prior to the first study-specific COC-cycle intake
  • History of alcohol abuse or drug addiction
  • Positive drug and alcohol screen at screening and (each) admission to the clinical research center
  • Average intake of more than 24 units of alcohol per week
  • Positive screen for hepatitis B surface antigen (HBsAg), anti-hepatitis C virus (HCV) antibodies or anti-human immunodeficiency virus (HIV) 1 and 2 antibodies
  • Participation in a drug study within 30 days prior to screening. Participation in more than 2 other drug studies in the 10 months prior to (the first) drug administration in the current study
  • Donation or loss of more than 100 mL of blood within 60 days prior to the start of Treatment Period A, on Day 1. Donation or loss of more than 1.0 liters of blood in the 10 months prior to the start of Treatment Period A, on Day 1
  • Significant and/or acute illness within 5 days prior to Day 1 in Treatment Period A, that may impact safety assessments, in the opinion of the investigator
  • Unsuitable veins for blood sampling

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Intervensjonsmodell: Sekvensiell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Pre-Treatment, Treatment Cycles A & B

Pre-Treatment: Two cycles of a combined oral contraceptive (COC) taken orally once daily for 21 days followed by 7 COC-free days.

Treatment Period A: COC containing taken orally once daily for 21 days followed by 7 COC-free days.

Treatment Period B: COC taken orally once daily for 21 days, with once daily oral 200 mg AQX-1125 (2 x 100 mg tablets) co-administered from Day 13 to 21, followed by 7 COC-free days

Investigational Drug
COC containing 100 ug Levonorgestrel (LNG) and 20 ug Ethinyl Estradiol (EE)

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Maximum observed plasma concentration (Cmax) of COC taken with AQX-1125
Tidsramme: 8 Weeks (from start of treatment period A to completion of treatment period B)
To assess the effect of multiple doses of 200 mg AQX-1125 once daily (qd) on the pharmacokinetics (PK) of the COC
8 Weeks (from start of treatment period A to completion of treatment period B)
Time to attain maximum observed plasma concentration (tmax) of COC taken with AQX-1125
Tidsramme: 8 Weeks (from start of treatment period A to completion of treatment period B)
To assess the effect of multiple doses of 200 mg AQX-1125 once daily (qd) on the pharmacokinetics (PK) of the COC
8 Weeks (from start of treatment period A to completion of treatment period B)
Area under the plasma concentration-time curve up to 24 hours (AUC0-24) of COC taken with AQX-1125
Tidsramme: 8 Weeks (from start of treatment period A to completion of treatment period B)
To assess the effect of multiple doses of 200 mg AQX-1125 once daily (qd) on the pharmacokinetics (PK) of the COC
8 Weeks (from start of treatment period A to completion of treatment period B)
Terminal elimination rate constant (Kel) of COC taken with AQX-1125
Tidsramme: 8 Weeks (from start of treatment period A to completion of treatment period B)
To assess the effect of multiple doses of 200 mg AQX-1125 once daily (qd) on the pharmacokinetics (PK) of the COC
8 Weeks (from start of treatment period A to completion of treatment period B)
Terminal elimination half-life (t1/2) of COC taken with AQX-1125
Tidsramme: 8 Weeks (from start of treatment period A to completion of treatment period B)
To assess the effect of multiple doses of 200 mg AQX-1125 once daily (qd) on the pharmacokinetics (PK) of the COC
8 Weeks (from start of treatment period A to completion of treatment period B)

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Safety and tolerability of AQX-1125 200 mg qd administered with the COC
Tidsramme: 16 weeks (from start of pre-treatment cycle 1 to completion of treatment period B)
Safety and tolerability will be assessed by the severity and frequency of adverse events, which will include any abnormal clinically significant vital signs, laboratory tests, electrocardiogram and physical examination findings
16 weeks (from start of pre-treatment cycle 1 to completion of treatment period B)
Maximum observed plasma concentration (Cmax) of AQX-1125 taken with COC
Tidsramme: 8 Weeks (from start of treatment period A to completion of treatment period B)
To assess the PK of 200 mg AQX-1125 qd when given together with the COC
8 Weeks (from start of treatment period A to completion of treatment period B)
Time to attain maximum observed plasma concentration (tmax) of AQX-1125 taken with COC
Tidsramme: 8 Weeks (from start of treatment period A to completion of treatment period B)
To assess the PK of 200 mg AQX-1125 qd when given together with the COC
8 Weeks (from start of treatment period A to completion of treatment period B)
Area under the plasma concentration-time curve up to 24 hours (AUC0-24) of AQX-1125 taken with COC
Tidsramme: 8 Weeks (from start of treatment period A to completion of treatment period B)
To assess the PK of 200 mg AQX-1125 qd when given together with the COC
8 Weeks (from start of treatment period A to completion of treatment period B)
Terminal elimination rate constant (Kel) of AQX-1125 taken with COC
Tidsramme: 8 Weeks (from start of treatment period A to completion of treatment period B)
To assess the PK of 200 mg AQX-1125 qd when given together with the COC
8 Weeks (from start of treatment period A to completion of treatment period B)
Terminal elimination half-life (t1/2) of AQX-1125 taken with COC
Tidsramme: 8 Weeks (from start of treatment period A to completion of treatment period B)
To assess the PK of 200 mg AQX-1125 qd when given together with the COC
8 Weeks (from start of treatment period A to completion of treatment period B)

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

22. november 2017

Primær fullføring (Faktiske)

29. mars 2018

Studiet fullført (Faktiske)

5. april 2018

Datoer for studieregistrering

Først innsendt

19. mars 2018

Først innsendt som oppfylte QC-kriteriene

23. mars 2018

Først lagt ut (Faktiske)

27. mars 2018

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

13. juni 2018

Siste oppdatering sendt inn som oppfylte QC-kriteriene

12. juni 2018

Sist bekreftet

1. juni 2018

Mer informasjon

Begreper knyttet til denne studien

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

produkt produsert i og eksportert fra USA

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere